Pentasa and Injection site extravasation - a phase IV clinical study of FDA data

Summary:

Injection site extravasation is reported as a side effect among people who take Pentasa (mesalamine), especially for people who are female, 60+ old, also take Humira, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Injection site extravasation when taking Pentasa. It is created by eHealthMe based on reports of 22,797 people who have side effects when taking Pentasa from the FDA, and is updated regularly.

What is Pentasa?

Pentasa has active ingredients of mesalamine. It is often used in crohn's disease. eHealthMe is studying from 23,325 Pentasa users. Check the latest studies of Pentasa.

What is Injection site extravasation?

Injection site extravasation (flow of (blood or lymph) from injection site) is found to be associated with 555 drugs and 728 conditions by eHealthMe. Check the latest studies of Injection site extravasation.

On Jul, 29, 2026

22,797 people reported to have side effects when taking Pentasa.
Among them, 20 people (0.09%) have Injection site extravasation.

Could Pentasa cause Injection site extravasation?

Among these 20 people:

What is the gender of people who have Injection site extravasation when taking Pentasa? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Injection site extravasation when taking Pentasa? *

What are other drugs people take besides Pentasa? *

Humira: 10 people, 50.00%
Tamsulosin: 2 people, 10.00%
Prednisolone: 2 people, 10.00%
Prednisone: 2 people, 10.00%
Zyrtec: 1 person, 5.00%
Depo-Provera: 1 person, 5.00%
Lantus: 1 person, 5.00%
Hydromorphone Hydrochloride: 1 person, 5.00%
Hydrochlorothiazide: 1 person, 5.00%
Folic Acid: 1 person, 5.00%

What are other side effects people have besides Injection site extravasation? *

Injection Site Pain: 5 people, 25.00%
Fatigue (feeling of tiredness): 5 people, 25.00%
Diarrhea: 4 people, 20.00%
Abdominal Pain: 4 people, 20.00%
Injection Site Haemorrhage (bleeding from injection site): 4 people, 20.00%
Nausea (feeling of having an urge to vomit): 2 people, 10.00%
Weakness: 2 people, 10.00%
Weight Decreased: 2 people, 10.00%
Blood Calcium Decreased: 1 person, 5.00%
Blood Glucose Decreased: 1 person, 5.00%

What are the existing conditions these people have? *

Weight Decreased: 1 person, 5.00%
Urinary Tract Infection: 1 person, 5.00%
Back Pain: 1 person, 5.00%
Birth Control: 1 person, 5.00%
Blood Pressure Abnormal: 1 person, 5.00%
Depression: 1 person, 5.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.00%
High Blood Cholesterol: 1 person, 5.00%
High Blood Pressure: 1 person, 5.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Pentasa and have Injection site extravasation?

- Check whether Injection site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pentasa:

Pentasa (23,325 reports)

Browse all side effects of Pentasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site extravasation:

Injection site extravasation (555 drugs)

Browse all the conditions that are associated with Injection site extravasation:

Injection site extravasation (728 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Pentasa) and Pentasa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.